We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Pathologists Use Spatial Light Interference Microscopy to Predict Risk of Prostate Cancer Recurrence Prior to Biopsy or Surgery

By LabMedica International staff writers
Posted on 24 May 2015
A novel microscopy method that combines phase contrast microscopy with holography enables prediction of the likelihood of prostate cancer recurrence prior to biopsy or surgery.

The method is called spatial light interference microscopy or SLIM. More...
SLIM uses a commercial phase contrast microscope and white light illumination, resulting in nanometer scale sensitivity to optical path-length shifts. In essence, SLIM combines phase contrast microscopy with holography.

Investigators at the University of Illinois (Urbana, USA) have introduced a new instrument for SLIM imaging. Their real-time fast SLIM technique could image at a maximum rate of 50 frames per second and provided real-time quantitative phase images at 12.5 frames per second. They were able to achieve this fast rate by combining rapid LCPM (linear pulse-code modulation) and a fast sCMOS camera. In addition, they developed the software to perform phase reconstruction and display the quantitative phase images in real-time.

In the current study, the investigators used the SLIM technique to examine 181 tissue samples obtained from the [US] National Cancer Institute-sponsored Cooperative Prostate Tissue Resource (CPCTR), The specimens were taken from individuals who had a prostatectomy, approximately half who had no recurrence and half who did.

The instrument was programmed to scan microscope slides containing 320–360 individual cores. The resulting SLIM image contained rich information about tissue morphology, with the glandular epithelium and stroma structures clearly resolved. This allowed the investigators to interrogate scattering changes specific to prostate stroma.

Results suggested that SLIM showed promise in assisting pathologists to improve prediction of prostate cancer recurrence. The data revealed that a lower value of anisotropy corresponded to a higher risk for recurrence, meaning that the stroma adjoining the glands of recurrent patients was more fractionated than in non-recurrent patients. Anisotropy is the property of being directionally dependent, as opposed to isotropy, which implies identical properties in all directions. It can be defined as a difference, when measured along different axes, in a material's physical or mechanical properties.

"For every 20 surgery procedures to take out the prostate, it is estimated that only one life is saved," said senior author Dr. Gabriel Popescu, associate professor of electrical and computer engineering at the University of Illinois. "For the other 19 people, they would be better left alone, because with removing the prostate, the quality of life goes down dramatically. So if you had a tool that could tell which patient will actually be more likely to have a bad outcome, then you could more aggressively treat that case."

"What SLIM is very good at is to make invisible objects visible with nanoscale sensitivity," said Dr. Popescu. "So we pick these structural details without the need for staining, which can introduce new variables into the specimen. Our dream is for everyone to have SLIM capabilities in their labs. One can imagine that a SLIM-based tissue imager will scan biopsies in a clinic and, paired with software that is intelligent enough to look for these specific markers, will provide the pathologist with valuable new information. This additional information will translate into more accurate diagnosis and prognosis."

The paper describing the use of SLIM to predict prostate cancer recurrence was published in the May 15, 2015, online edition of the journal Scientific Reports.

Related Links:

University of Illinois



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: GRAIL’s Galleri test uses machine learning to analyze cfDNA patterns for cancer signals and predict their likely location to guide further evaluation.

Multi-Cancer Blood Test Expands Detection to Cancers Lacking Routine Screening Options

Many lethal cancers lack routine screening and are often diagnosed only after symptoms emerge, limiting curative options. Standard programs in the United States cover a small subset of malignancies, leaving... Read more

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.